Price Target Changed • Jun 16
Price target decreased by 9.5% to US$5.43 Down from US$6.00, the current price target is an average from 7 analysts. New target price is 732% above last closing price of US$0.65. Stock is up 13% over the past year. The company is forecast to post a net loss per share of US$0.39 next year compared to a net loss per share of US$0.38 last year. New Risk • Jun 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 16% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$67m net loss in 3 years). Announcement • Jun 15
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for Ctim-76 Context Therapeutics Inc. announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer. The data are as of a May 29, 2026 data cutoff from the ongoing CTIM-76 Phase 1 study. CTIM-76 has been granted FDA Fast Track Designation in platinum-resistant ovarian cancer. 21 patients with platinum-resistant ovarian cancer (n=14), testicular (n=4), and endometrial (n=3) cancer were treated with CTIM-76 at doses ranging from 22.5µg to 560µg every week. At the active doses of 140µg to 280µg, 13 patients were treated in total, 10 of whom were efficacy evaluable, having had at least one post-baseline tumor assessment as of the data cutoff. 560µg exceeded target exposures with weekly dosing and was not pursued further. Patients (n=9) received a median of 7 prior lines of therapy (range 5-16). Prior patient treatments included ADC (89%), checkpoint inhibitor (55%), VEGF (100%), or DNA repair agent (78%). 44% of patients had liver metastases. As of the data cutoff, 7 platinum-resistant ovarian cancer patients were efficacy-evaluable at doses of 140µg to 280µg. Overall response rate: 29% of platinum-resistant ovarian cancer patients (2/7) achieved confirmed partial RECIST v. 1.1 responses. Disease control rate: 57% (4/7). In early cohort patients who achieved confirmed stable disease or partial response, treatment durability was sustained for at least 6 months (n=3). At active dose levels, CTIM-76 produced a favorable safety profile that is consistent with the expected mechanism of action for a T cell engager and supports continued clinical development. Adverse events generally occurred during the first or second dose and were predominantly low grade, with the majority of events reported as Grade 1 or Grade 2 and reversible with standard management. Cytokine Release Syndrome events were infrequent and limited to Grade 1 (11%, n=1/9) at active dose levels in platinum-resistant ovarian cancer patients, which may be supportive of outpatient dosing in future trials. Approximately dose-dependent increases in CTIM-76 exposure with increasing dose level. Preliminary pharmacokinetic supports exploration of every three weeks dosing schedule. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov. Disease Control Rate: Patients achieving a confirmed response of stable disease, partial response, or complete response. 
